MX9400138A - Una preparacion farmaceutica de liberacion retardada prolongada. - Google Patents
Una preparacion farmaceutica de liberacion retardada prolongada.Info
- Publication number
- MX9400138A MX9400138A MX9400138A MX9400138A MX9400138A MX 9400138 A MX9400138 A MX 9400138A MX 9400138 A MX9400138 A MX 9400138A MX 9400138 A MX9400138 A MX 9400138A MX 9400138 A MX9400138 A MX 9400138A
- Authority
- MX
- Mexico
- Prior art keywords
- diffusion barrier
- pharmaceutical preparation
- release
- medicine
- additive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una preparación farmacéutica de liberación retardada prolongada se provee en la cual un núcleo de medicamento soluble en agua está rodeado por una barrera de difusión hidratable que retarda la liberación de medicamento durante 2-10 horas. La barrera de difusión hidratable comprende un polímero formador de película tal como una resina arílica o etil celulosa y un aditivo que controla la tasa de hidratación y la permeabilidad de la barrera de difusión hidratable seleccionada del grupo que consiste de resinas acrílicas completamente esterificadas que contienen cadenas laterales de aminas cuaternarias, lubricantes, surfactantes aniónicos, plastificantes materiales solubles en agua inertes, y sus mezclas. En una preparación farmacéuticas de liberación prolongada preferida, el polímero formador de película se combina con el aditivo y se usa para recubrir los gránulos de medicamentos nucleares para producir una barrera de difusión que rodee al medicamento del núcleo y forme micropartículas que entonces pueden mezclarse con un medicamento de liberación inmediata.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/996,097 US5376384A (en) | 1992-12-23 | 1992-12-23 | Delayed, sustained-release pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9400138A true MX9400138A (es) | 1994-07-29 |
Family
ID=25542501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9400138A MX9400138A (es) | 1992-12-23 | 1994-01-03 | Una preparacion farmaceutica de liberacion retardada prolongada. |
Country Status (8)
Country | Link |
---|---|
US (3) | US5376384A (es) |
EP (1) | EP0605174B1 (es) |
JP (1) | JPH072657A (es) |
AU (1) | AU665733B2 (es) |
CA (1) | CA2110853A1 (es) |
DE (1) | DE69319320T2 (es) |
HU (1) | HUT75683A (es) |
MX (1) | MX9400138A (es) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5560928A (en) * | 1995-06-23 | 1996-10-01 | Defelice; Stephen L. | Nutritional and/or dietary composition and method of using the same |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
FR2742660B1 (fr) | 1995-12-22 | 1998-04-03 | Ethypharm Lab Prod Ethiques | Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif |
WO1997032573A1 (en) * | 1996-03-08 | 1997-09-12 | Nycomed Danmark A/S | Modified release multiple-units dosage composition |
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
DE19631084A1 (de) * | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut |
GB9620709D0 (en) * | 1996-10-04 | 1996-11-20 | Danbiosyst Uk | Colonic delivery of weak acid drugs |
JP4863534B2 (ja) * | 1996-10-25 | 2012-01-25 | スパーナス ファーマシューティカルズ インコーポレイテッド | 可溶形態浸透用量送達システム |
US6361796B1 (en) | 1996-10-25 | 2002-03-26 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US6337091B1 (en) * | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
DE19808634A1 (de) * | 1998-02-24 | 1999-08-26 | Schering Ag | Mantel für eine pharmazeutische Zusammensetzung |
US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US6110500A (en) * | 1998-03-25 | 2000-08-29 | Temple University | Coated tablet with long term parabolic and zero-order release kinetics |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
DE69937805T2 (de) * | 1998-10-07 | 2008-12-04 | Kyowa Hakko Kogyo Co., Ltd. | Verfahren zur stabilisierung eines wirkstoffes in einer tablette |
AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
CN100391438C (zh) * | 1999-09-14 | 2008-06-04 | 史密丝克莱恩比彻姆公司 | 制备水性包被小球粒的方法 |
US7108866B1 (en) * | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
CZ300745B6 (cs) * | 1999-12-22 | 2009-07-29 | Pharmacia Corporation | Kompozice inhibitoru cyklooxygenázy-2 s dvojím uvolnováním |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
JP3610431B2 (ja) * | 2000-07-17 | 2005-01-12 | マークテック株式会社 | 湿式磁粉探傷試験用磁粉配合物 |
US6984402B2 (en) | 2000-10-03 | 2006-01-10 | Elite Laboratories, Inc. | Chrono delivery formulations and method of treating atrial fibrillation |
US6620439B1 (en) | 2000-10-03 | 2003-09-16 | Atul M. Mehta | Chrono delivery formulations and method of use thereof |
AU2002221273A1 (en) * | 2000-10-26 | 2002-05-06 | Atul M. Mehta | Delayed and sustained release formulations and method of use thereof |
SE0100200D0 (sv) * | 2001-01-24 | 2001-01-24 | Astrazeneca Ab | New film coating |
WO2002064654A1 (fr) * | 2001-02-09 | 2002-08-22 | Reika Kogyo Kabushiki Kaisha | Particule fonctionnelle, procede de preparation de celle-ci et procede de traitement par plasma |
US7052706B2 (en) * | 2001-06-08 | 2006-05-30 | Nostrum Pharmaceuticals, Inc. | Control release formulation containing a hydrophobic material as the sustained release agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
EP1443910A1 (en) * | 2001-11-02 | 2004-08-11 | Wockhardt Limited | Controlled release compositions for macrolide antimicrobial agents |
US20050025824A1 (en) * | 2001-12-14 | 2005-02-03 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
US6663888B2 (en) * | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
DE60202662T2 (de) * | 2001-12-19 | 2006-01-05 | Astrazeneca Ab | NEUE FILMBESCHICHTUNG enthaltend ein Äthylacrylate/Methylmethacrylate-copolymer und Polyvinylacetat |
CA2470636A1 (en) * | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
MXPA04008100A (es) * | 2002-02-21 | 2005-06-17 | Biovail Lab Int Srl | Formulaciones de liberacion modificada de al menos una forma de tramadol. |
US8323692B2 (en) * | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
US7022342B2 (en) | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
SE0201110D0 (sv) * | 2002-04-12 | 2002-04-12 | Astrazeneca Ab | New film coating |
US20040005359A1 (en) * | 2002-06-27 | 2004-01-08 | Cheng Xiu Xiu | Controlled release oral dosage form |
SE0202353D0 (sv) * | 2002-08-01 | 2002-08-01 | Astrazeneca Ab | New film coating |
MXPA05002623A (es) * | 2002-09-09 | 2005-05-05 | Biovail Lab Inc | Formulaciones cronoterapeuticas de diltiazem y la administracion de las mismas. |
EP1551372B8 (en) * | 2002-09-20 | 2018-08-01 | Alpharma Pharmaceuticals LLC | Sequestering subunit and related compositions and methods |
US20040091528A1 (en) * | 2002-11-12 | 2004-05-13 | Yamanouchi Pharma Technologies, Inc. | Soluble drug extended release system |
AU2003297561A1 (en) * | 2002-11-26 | 2004-06-18 | Garry R. Hollenbeck | Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
US20040185032A1 (en) * | 2003-03-18 | 2004-09-23 | David Burrell | Compositions and methods for treating colic |
US7115283B2 (en) * | 2003-05-06 | 2006-10-03 | Access Business Group International Llc | Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals |
CA2461223C (en) * | 2004-03-16 | 2013-05-28 | Stanley Phillips | Apparatus for generating ozone and/or o1 using a high energy plasma discharge |
EP1737433B1 (en) * | 2004-04-12 | 2007-11-14 | Pfizer Products Incorporated | Taste-masked drugs in rupturing multiparticulates |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
WO2006009810A1 (en) * | 2004-06-17 | 2006-01-26 | Sun Chemical B.V. | Devices and methods for product authentication and/or monitoring |
EP2404605B1 (en) | 2004-08-25 | 2015-04-22 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
NZ728442A (en) | 2004-10-21 | 2018-05-25 | Adare Pharmaceuticals Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
EP1830648A4 (en) * | 2004-12-09 | 2008-03-12 | Celgene Corp | TREATMENT WITH D-THREO-METHYLPHENIDATE |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
DK1915137T3 (da) | 2005-08-10 | 2013-11-04 | Add Advanced Drug Delivery Technologies Ltd | Oralt præparat med kontrolleret frisætning |
TWI274889B (en) * | 2005-10-06 | 2007-03-01 | Elan Microelectronics Corp | Resistive touch screen measurement system |
JP5543110B2 (ja) | 2006-01-05 | 2014-07-09 | エッセンシャリス,インク. | カリウムatpチャネルオープナの塩およびその使用 |
EP2526932B1 (en) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition |
CA2670636A1 (en) | 2006-11-27 | 2008-06-05 | H. Lundbeck A/S | Heteroaryl amide derivatives |
US11116728B2 (en) | 2006-11-30 | 2021-09-14 | Bend Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
WO2008065504A1 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
US20080187579A1 (en) * | 2007-02-01 | 2008-08-07 | Pavan Bhat | Extended-release dosage form |
CN101795691A (zh) * | 2007-07-02 | 2010-08-04 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的盐及其用途 |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
WO2009143072A1 (en) * | 2008-05-19 | 2009-11-26 | Wynden Pharmaceuticals, Inc. | High-loading, controlled-release magnesium oral dosage forms and methods of making and using same |
MX2012006240A (es) | 2009-12-02 | 2012-10-03 | Aptalis Pharma Ltd | Microcapsulas de fexofenadina y composiciones que contienen las mismas. |
CA2835293C (en) | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
WO2020207471A1 (en) * | 2019-04-12 | 2020-10-15 | Medical And Pharmaceutical Industry Technology And Development Center | Modified release pharmaceutical composition and method for the treatment of mental disorders |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155590A (en) * | 1962-08-02 | 1964-11-03 | Ncr Co | Encapsulation process and its product |
US3341416A (en) * | 1963-12-11 | 1967-09-12 | Ncr Co | Encapsulation of aspirin in ethylcellulose and its product |
US3531418A (en) * | 1965-08-18 | 1970-09-29 | Ncr Co | En masse encapsulation process |
US3488418A (en) * | 1965-11-18 | 1970-01-06 | Sterling Drug Inc | Sustained relief analgesic composition |
US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4205060A (en) * | 1978-12-20 | 1980-05-27 | Pennwalt Corporation | Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use |
JPS597363B2 (ja) * | 1979-07-13 | 1984-02-17 | 旭光学工業株式会社 | コンパクトなズ−ムレンズ系 |
JPS5611687A (en) * | 1980-06-02 | 1981-02-05 | Fujitsu Ltd | Semiconductor memory unit |
EP0052075A1 (de) * | 1980-11-12 | 1982-05-19 | Ciba-Geigy Ag | Körnige Arzneimittel-Retardform |
ZA822995B (en) * | 1981-05-21 | 1983-12-28 | Wyeth John & Brother Ltd | Slow release pharmaceutical composition |
JPS5867616A (ja) * | 1981-10-15 | 1983-04-22 | Tanabe Seiyaku Co Ltd | 腸溶性マイクロカプセル |
AU571312B2 (en) * | 1984-02-10 | 1988-04-14 | Nycomed Danmark A/S | Diffusion coated multiple-units dosage form |
JPS6215A (ja) * | 1985-02-26 | 1987-01-06 | Fujisawa Pharmaceut Co Ltd | 2−ニトロオキシメチル−6−クロロピリジンまたはそのβ−シクロデキストリン包接化合物含有持続性製剤 |
US4772475A (en) * | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
DE3678641D1 (de) * | 1985-08-16 | 1991-05-16 | Procter & Gamble | Partikel mit konstanter wirkstofffreisetzung. |
GB8618811D0 (en) * | 1986-08-01 | 1986-09-10 | Approved Prescription Services | Sustained release ibuprofen formulation |
US4752470A (en) * | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
JPS63188621A (ja) * | 1987-01-30 | 1988-08-04 | Taisho Pharmaceut Co Ltd | 矯味経口製剤 |
US5057317A (en) * | 1987-03-24 | 1991-10-15 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
US4968509A (en) * | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US4983401A (en) * | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
US5188836A (en) * | 1990-07-27 | 1993-02-23 | Warner-Lambert Company | Sustained release formulations |
ES2073301T3 (es) * | 1991-05-20 | 1995-08-01 | Marion Laboratories Inc | Composicion multi-capa de liberacion controlada. |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
-
1992
- 1992-12-23 US US07/996,097 patent/US5376384A/en not_active Expired - Fee Related
-
1993
- 1993-12-06 AU AU52175/93A patent/AU665733B2/en not_active Ceased
- 1993-12-07 CA CA002110853A patent/CA2110853A1/en not_active Abandoned
- 1993-12-17 HU HU9303626A patent/HUT75683A/hu unknown
- 1993-12-21 DE DE69319320T patent/DE69319320T2/de not_active Expired - Fee Related
- 1993-12-21 EP EP93310372A patent/EP0605174B1/en not_active Expired - Lifetime
- 1993-12-24 JP JP5326627A patent/JPH072657A/ja active Pending
-
1994
- 1994-01-03 MX MX9400138A patent/MX9400138A/es not_active Application Discontinuation
- 1994-12-12 US US08/353,919 patent/US5478573A/en not_active Expired - Fee Related
- 1994-12-12 US US08/354,378 patent/US5529790A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2110853A1 (en) | 1994-06-24 |
US5529790A (en) | 1996-06-25 |
DE69319320T2 (de) | 1999-02-11 |
US5376384A (en) | 1994-12-27 |
HU9303626D0 (en) | 1994-04-28 |
JPH072657A (ja) | 1995-01-06 |
AU5217593A (en) | 1994-07-07 |
HUT75683A (en) | 1997-05-28 |
AU665733B2 (en) | 1996-01-11 |
EP0605174B1 (en) | 1998-06-24 |
DE69319320D1 (de) | 1998-07-30 |
EP0605174A1 (en) | 1994-07-06 |
US5478573A (en) | 1995-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9400138A (es) | Una preparacion farmaceutica de liberacion retardada prolongada. | |
PE71699A1 (es) | Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra | |
ZA90971B (en) | Medicaments having controlled release of the active compound | |
DE69331806T2 (de) | Multipartikel-arzneistoffabgabesystem mit stossweiser freisetzung | |
KR880001285A (ko) | 약용 서방 기제 | |
CA2016039A1 (en) | Extended release pharmaceutical formulations | |
ES2001897A6 (es) | Procedimiento para la fabricacion de una tableta de liberacion controlada | |
AU7979094A (en) | Methods and compositions for microencapsulation of adjuvants | |
SE8404467D0 (sv) | Controlled-release medical preparations | |
BR0206441A (pt) | Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica de liberação modificada, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula e uma formulação | |
DE69626117D1 (de) | Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung von reversiblen protonpumpen-inhibitoren | |
DE69229881D1 (de) | Tablette mit verzögerter freisetzung | |
DK0632720T3 (da) | Hydroxyethylcellulosebaserede depotpræparat-doseringsformer | |
ES2110701T3 (es) | Proceso para la preparacion de catalizadores utiles en la produccion de acetato de vinilo. | |
AR065072A2 (es) | Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo | |
DE69209080D1 (de) | Pharmazeutische zusammemsetzungen mit verzoegerter freigabe | |
AR011133A1 (es) | MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA. | |
GEP19991686B (en) | Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same | |
DK616186A (da) | Farmaceutisk praeparat med retarderet frigivelse af ibuprofen | |
EP0616802A4 (en) | PREPARATION ORALLY ADMINISTERED TO BE RELEASED IN THE LOWER DIGESTIVE TUBE. | |
IL103329A0 (en) | Imidazole-5-carboxylic acid acylals,their preparation and pharmaceutical compositions containing them | |
DE69131047D1 (de) | Pharmazeutische zusammensetzungen | |
ES2187038T3 (es) | Glicosidos modificados, composiciones que los comprenden y procedimientos para su utilizacion. | |
ES2058075T3 (es) | Procedimiento para granular una sal de azobisamidina. | |
GB1108299A (en) | Sustained release dosage forms and their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |